Navigation Links
For sharper pictures of the body's interior
Date:1/28/2009

Below in the Annex: ("We are breaking new ground in research"), you will find an interview with PTB project head Dr. Bernd Ittermann on the opportunities and risks of the whole-body tomographs of the new 7-tesla generation at the Max-Delbrck-Centrum (Max Delbrck Center) in Berlin.

Snap-shots of a diseased heart or deep insights into cancer cells a 7-tesla magnetic resonance tomograph promises scientists novel possibilities. The magnetic field of this so-called ultra-high field magnetic resonance tomograph (MRT) is 140 000 times as strong as that of the Earth and can make the most minute structures of the human body visible. This facilitates not only the development of possibilities for diagnosis and therapy in the case of brain and cancer diseases, but also opens up completely new possibilities, among other things, in cardiac research. One of the project partners is the Physikalisch-Technische Bundesanstalt (PTB, the National German Metrology Institute), whose scientists want to explore the technical possibilities of the new device and make it useful for clinical application. This week, the corresponding research building in the Experimental and Clinical Research Center of the Max-Delbrck-Centrum fr Molekulare Medizin (Max Delbrck Center for Molecular Medicine) in Berlin-Buch was dedicated during a visit by the Federal Research Minister Annette Schavan.

As the fourth 7-tesla MRT worldwide (after Boston, Pittsburgh and Paris), the Berlin System is equipped with an 8-channel transmitter system, and with this technology the cardiac imaging by means of 7-tesla MRT moves into the public eye for the first time. New research ground could also be broken in the representation of molecular processes in the body, for example in combating tumours. Bernd Ittermann, head of the Department of Medical Metrology at the PTB, explains: "So far there are only about 30 magnetic resonance tomographs with such a high magnetic field strength, and most of them are used for brain research". The new whole-body MRT at the Max Delbrck Center is to, however, have considerably more widespread use. The machine will provide pictures of extremely high resolution from the interior of the body of test persons. The researchers expect to receive insights into the development of diseases and the metabolic processes involved.

In clinics, MRT machines with 1.5 or 3 tesla (that is the unit for the magnetic flux) are customary. The 7-tesla tomograph will at first be purely a research instrument in order to explore the possibilities of the ultra-high-field magnetic resonance tomography. It is the only machine worldwide of the modern 7-tesla generation in which also a metrology institute is involved. "I find exemplary how physicians, physicists, mathematicians and engineers of the involved institutes have joined forces here in order to open up a new dimension in medical diagnostics", rejoiced PTB President Professor Dr. Ernst Gbel.

The stray magnetic field of the magnet, weighing 32 tonnes is so strong that all objects containing iron are strongly prohibited in its direct proximity. Only outside of a cage nearly five meters high and 14 meters long and made of 250 tonnes of steel is the field shield strong enough, for example, for the operation of computers.

The project partners are in addition to the Max Delbrck Center and the PTB, also the Berlin Charit, the Leibnizinstitut fr Molekulare Pharmakologie (Leibniz Institute of Molecular Pharmacology) and the Siemens company.


'/>"/>

Contact: Dr. Bernd Ittermann
Bernd.Ittermann@ptb.de
49-303-481-7318
Physikalisch-Technische Bundesanstalt (PTB)
Source:Eurekalert

Related medicine news :

1. The Help Groups Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins
2. Harpo Productions and Sony Pictures Television Announce Agreement to Launch DR. OZ
3. Novartis and Sony Pictures Television Internationals Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... , ... IndustryArchive.Org . is announcing a new way for B2B Sellers ... only pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase ... reality that B2B buyers are controlling the sales process via the Internet and that ...
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure ... a specific LRRK2 mutation, according to a study released today at the 1st ... of a link between pesticides and incidence of sporadic PD through occupational exposure. ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... its newly designed TaskMate Go. Core benefits and advantages built into the home ... a stylish, functional look and feel. Ability to gain the benefits embedded in ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the ... Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run of ... book measures almost a metre across when open, weighs in at more than six ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
(Date:2/24/2017)... Wyoming , Feb. 24, 2017  Xynomic Pharmaceuticals, ... today announced that it has acquired exclusive worldwide ... potentially best-in-class innovative HDAC inhibitor targeting hematological and ... of 14 Phase 1 and 2 clinical trials ... Asia have already been completed, demonstrating ...
Breaking Medicine Technology: